{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-040385","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.833344+00:00","generated_at":"2026-06-24T11:25:50.162684+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"InMed appoints Michael Woudenberg as COO effective July 15, 2022","bullets":["Michael Woudenberg appointed Chief Operating Officer, effective July 15, 2022.","Previously served as SVP of Chemistry, Manufacturing and Controls.","Employment agreement provides C$300,000 annual base salary.","Eligible for annual discretionary bonus targeted at 40% of base salary.","Woudenberg has over 20 years of drug development and GMP manufacturing experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-040385","json":"https://secwatch.observer/filing/0001213900-22-040385.json","markdown":"https://secwatch.observer/filing/0001213900-22-040385.md","text":"https://secwatch.observer/filing/0001213900-22-040385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/0001213900-22-040385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/ea163069-8k_inmedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:25:50.162684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7320fcf3b","claim":"Michael Woudenberg was appointed as Chief Operating Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"On July 18, 2022, InMed Pharmaceuticals Inc. (the “Company”) issued a press release to announce that it has appointed Mr. Michael Woudenberg as the Company’s Chief Operating Officer effective July 15, 2022 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022040385/0001213900-22-040385-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}